- Patients in hospital-at-home programs had lower in-hospital mortality, fewer emergency department visits within 30 days of discharge, and less frequent ICU escalation compared with patients in traditional inpatient care, according to a JAMA Network Open study of Medicare beneficiaries.
- Hospital-at-home patients also saw lower rates of hospital-acquired complications such as infections, and experienced “minor decreases” in total healthcare costs — though care duration was longer than in conventional settings.
- No significant difference in 30-day hospital readmissions was found between the two groups, and adoption remains highly uneven: among 68 hospitals studied, 11 accounted for half of all hospital-at-home admissions, all in urban areas, concentrated in the Northeast and South.
- Congress extended the CMS Acute Hospital Care At Home program through September 2030 earlier this year, which experts say could incentivize more hospitals to build programs — but rural access remains a significant barrier due to internet infrastructure, travel distances, and staffing constraints.
What Happened?
Researchers publishing in JAMA Network Open this week analyzed Medicare beneficiary data from hospitals with at least 12 hospital-at-home admissions in 2021 and 2022, comparing outcomes against matched patients receiving traditional inpatient care. The results favored hospital at home across several key clinical metrics: lower in-hospital mortality, reduced ED utilization within 30 days, fewer ICU escalations, and lower rates of hospital-acquired infections. Total healthcare costs were modestly lower, though the length of care episodes was longer. The study adds to a growing body of evidence supporting hospital at home as a clinically viable model — not just a cost-cutting measure or a pandemic-era stopgap.
Why It Matters?
Hospital at home sits at the intersection of several major healthcare trends: the push to free up inpatient capacity, the desire to reduce costly hospital-acquired complications, and the growth of remote monitoring technology that makes home-based acute care increasingly feasible. The JAMA findings are particularly timely because Congress just extended the CMS Acute Hospital Care At Home waiver program through September 2030 — giving hospitals a long enough runway to justify the capital investment required to build programs. The clinical outcome data also matters for payer negotiations: if hospital at home can demonstrate lower mortality and complication rates, it strengthens the case for permanent reimbursement structures rather than waiver-dependent funding. However, the extreme geographic concentration of adoption — with zero high-utilizer programs in the West and only one in the Midwest — means the model’s benefits are currently accruing almost entirely to urban patients in a handful of health systems.
What’s Next?
The 2030 extension of the CMS waiver is expected to catalyze new program launches, particularly among large urban health systems that have the technology infrastructure and patient volumes to make hospital at home financially viable. Researchers are calling for policy interventions to address the equity gap — specifically, investments in rural broadband, telehealth infrastructure, and workforce models that can support home-based acute care in lower-density markets. As AI-powered remote monitoring and predictive deterioration tools improve, the clinical feasibility of managing complex patients at home will expand. The next key policy question is whether CMS moves toward making hospital-at-home reimbursement permanent — rather than repeatedly extending a temporary waiver — which would unlock longer-term capital investment from hospital systems currently reluctant to commit to an uncertain reimbursement future.
Source: Healthcare Dive
